This model of selectively testing only certain index cases (i.e., those with a positive tumour test result) for germline BRCA1/2 pathogenic variants relies on tumour tests being able to detect all types of BRCA1/2 pathogenic/likely pathogenic variant, including point mutations, small insertions and deletions, and large rearrangements. This evidence concerns the gene BRCA1 and neoplasm.